Drugs /

folfox regimen

Back to Drugs List

Overview

NCI Definition [1]:
One of several chemotherapy regimens that include leucovorin calcium (calcium folinate), 5-fluorouracil and oxaliplatin and which may be used in the treatment of advanced-stage and metastatic colorectal cancer. FOLFOX regimens differ in agent dosing and administration schedule and include FOLFOX 4, FOLFOX 6, modified FOLFOX 6 (mFOLFOX 6) and FOLFOX 7.

Clinical Trials

View Clinical Trials for folfox regimen

Folfox regimen has been investigated in 27 clinical trials, of which 20 are open and 7 are closed. Of the trials investigating folfox regimen, 5 are phase 1 (2 open), 7 are phase 1/phase 2 (6 open), 13 are phase 2 (10 open), and 2 are phase 3 (2 open).

ERBB2 Amplification, HER2 Overexpression, and HER2 Positive are the most frequent biomarker inclusion criteria for folfox regimen clinical trials.

Adenocarcinoma of the gastroesophageal junction, colorectal carcinoma, and gastric adenocarcinoma are the most common diseases being investigated in folfox regimen clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Folfox Regimen
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Folfox Regimen
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating folfox regimen and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
folfox-6, folfox-6 regimen, folfox-7 regimen, fluorouracil/leucovorin calcium/oxaliplatin, folfox, cf/5-fu/l-ohp
NCIT ID [1]:
C11197

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.